Organisation: Antegren

A COMPREHENSIVE SERIES OF ARTICLES ON THIS TOPIC

business

MS treatment expected to be available here next year

THE MS treatment known as Tysabri, which is expected to generate €1 billion in annual sales for Elan, is expected to be available in Ireland late next year.

business

Elan announces completion of $1.15bn offering

business

Positive results from Elan and Biogen

business

Market report: Elan stock surges after Antegren annoucement

business

Elan: Antegren study 'positive'

business

Elan looks to future despite results

Fillip for Elan on SEC settlement

ELAN is finally emerging from the confidence crisis that hit the company in 2002, resulting in a massive fall in its share price, with the announcement of a settlement with the US Securities and Exchange Commission.

Wed, 27 Oct, 2004

Elan dismisses rumour of merger

SHARES in Elan gained as much as 8% yesterday before the company dismissed weekend reports that it was in merger talks with an American drug firm.

Tue, 19 Oct, 2004

Lack of trading weighs on market

THE Irish market continued its negative trend, shedding 5.95 points to close at 5593.19. Lack of trading and very little news flow weighed on the index.

Fri, 15 Oct, 2004

Antegren goes for European approval

ELAN submitted its flagship Antegren drug for approval by European regulators as a treatment for Crohn’s disease yesterday, saying tests showed it worked over a 12-month period.

Thu, 30 Sep, 2004

Banks help FTSE into positive territory

The ISEQ index closed in positive territory today, climbing 34.54 to 5.661.46, buoyed by a strong performance by financial stocks.

Wed, 29 Sep, 2004

Shares in Elan drop by 7%

ELAN shares tumbled almost 7% in Dublin yesterday after it said it would hold off on releasing data from trials of its Antegren drug.

Thu, 19 Aug, 2004

Buoyant trade in financial shares

SHARES in Dublin traded solidly yesterday, with the ISEQ index finishing 14.59 points higher at 5351.51.

Tue, 27 Jul, 2004

US regulators to speed up drug review

US drug regulators have agreed to speed up a review of Elan’s application to market a treatment for Multiple Sclerosis.

Tue, 27 Jul, 2004

Elan hugely undervalued, says Bloxham

BLOXHAM Stockbrokers believe Elan is still massively undervalued and has set a $45 price target for the share, up 86% on the €24.23 price range the shares have been trading.

Thu, 15 Jul, 2004

Backing for MS drug boosts Elan

SHARES in Elan soared by 5.91% yesterday, adding €444 million to the value of the company.

Tue, 29 Jun, 2004

Irish firm surges on back of MS drug

Elan Corporation, the long-troubled Irish drugs maker now on the rebound, surged on stock markets today after reporting that its trial drug for treating multiple sclerosis, Antegren, has been fast-tracked for potential approval in the United States.

Mon, 28 Jun, 2004

Elan announces key appointments

Pharmaceutical giant Elan today announced a number of major appointments to the organisation.

Thu, 17 Jun, 2004

Elan starts to produce MS drug

ELAN has started production of Antegren, its multiple sclerosis (MS) drug, in advance of a possible launch in 2005.

Wed, 16 Jun, 2004

Faster eircom DSL roll-out may begin to generate broadband return

The ISEQ was down 24.98 points to 5155.89 today.

Tue, 25 May, 2004

Elan submits MS data for trial drug Antegren

Irish pharmaceutical firm Elan and partner Biogen announced today that they have submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for the approval of Antegren for the treatment of multiple sclerosis (MS).

Tue, 25 May, 2004

ISEQ just behind positive bourses

EUROPEAN markets were in positive form yesterday with most bourses gaining around 2%.

Thu, 20 May, 2004

Iseq climbs, led by Elan boost

The Iseq index of Irish shares rose steadily today, to close up 52.84 points at 5232.42.

Wed, 19 May, 2004

Elan shares jump on reduction of losses

SHARES in Elan gained as much as 7% yesterday as the drug firm posted a sharp reduction in first quarter losses.

Fri, 14 May, 2004

Elan shares rise 8% after Moody’s upgrade

ELAN shares rose again yesterday after Moody’s Investors Services upgraded the outlook on its debt to positive from stable and confirmed its current ratings.

Tue, 20 Apr, 2004

Elan up on expected 2005 product launch

The ISEQ index of Irish shares closed down 29.77 points to 5375.06 today.

Wed, 14 Apr, 2004

Elan sells epilepsy drug to Eisai

Troubled pharmaceutical company Elan has sold its interests in epilepsy drug Zonegran. Eisai will pay $130m to Elan if the transaction is completed by April 30 but less if the deal takes place after that.

Thu, 01 Apr, 2004

Elan shares gain nearly 5% as MS drug planned

SHARES in Elan gained nearly 5% yesterday after the drug group said it was looking to launch a treatment for Multiple Sclerosis (MS) in Europe.

Wed, 24 Mar, 2004

Elan and Biogen Idec submit for Antegren approval

Pharmaceuticals giant Elan and drug developer Biogen Idec have announced plans to submit to the European Agency for the Evaluation of Medicinal Products (EMEA) for approval of Antegren, a treatment for multiple sclerosis (MS).

Tue, 23 Mar, 2004

Elan shareholders given a boost

IT was like the good old days for Elan shareholders, with a €1.4 billion rise in the value of the company’s stock in the last two days.

Fri, 20 Feb, 2004

Elan sees 2003 total revenue drop by a third

Pharmaceutical giant Elan has reported that total revenue for 2003 fell 34% on 2002's figure, to $746m (€578.59m).

Wed, 18 Feb, 2004